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Background
In preclinical studies, PEGylated IL-10 (PEG-IL-10) but
not non-PEG IL-10 induces tumor rejection by the
directly activating and increasing the proliferation of
tumor specific CD8 T cells within the tumor. PEG-IL-
10 activates STAT3 and STAT1 in tumor infiltrating
CD8 T cells. PEG-IL-10 induced the expression of the
Th1 signature cytokine IFNg in intratumoral CD8
T cells, which was crucial for the tumor immunity.
Concomitant application of PEG-IL-10 and che-
motherapies did not disrupt the immune stimulation
but lead to synergistic anti-tumor efficacy.
Phase I study with AM0010 (PEG-hIL-10) has enrolled
more than 200 patients in monotherapy and in combina-
tion arms with chemotherapies, a tyrosine kinase inhibi-
tor and a PD-1 inhibitor. Primary objectives of this study
were to establish the safety, tolerability and the MTD of
AM0010 as monotherapy or in combination with che-
motherapies, targeted agents or immunotherapy. Second-
ary objectives were to assess anti-tumor-activity,
pharmacokinetics, immunogenicity and AM0010 induced
immune activation.
Results
Dose escalation ranged from 1-40 mcg/kg daily in mono-
therapy. An MTD for monotherapy was not defined, but
the recommended Phase II dose (RP2D) was defined as
20-40 mcg/kg. The half-life of AM0010 is ~20hrs. Com-
mon treatment related adverse events (AEs) included
injection site reaction, rash, fatigue, thrombocytopenia
and anemia. G3 adverse events in the monotherapy
cohorts included anemia, thrombocytopenia, rash and
fatigue. AEs promptly improved upon dose interruption
and durable immune related AEs were not observed.
At RP2D, AM0010 induced a signature immune cyto-
kine profile in the serum of all patients. It included the
upregulation of cytokines IL-18 and IFNg (Th1), IL-4 and
GM-CSF (dendritic cell maturation), IL-7 (T cell memory)
and FasL (cytotoxic T cells). The immune suppressive
cytokine TGFb was down-regulated.
The percentage of CD8 T cells positive for the activa-
tion marker PD1 increased in the blood of responding
patients. Objective responses in AM0010 monotherapy
were observed in 11% of immune sensitive cancers
(RCC, NSCLC, melanoma). Disease control rate (DCR)
across all 10 indications enrolled (including pancreatic
and colorectal cancer) was 49%.
Combination with chemotherapies resulted in 78%
DCR and 22% PRs across all 17 indications. Combination
studies with anti-PD-1 antibodies are in progress and
preliminary clinical results indicate synergistic anti-
tumor activity in immune sensitive indications.
Conclusions
AM0010 was well tolerated and lead to sustained and sys-
temic Th1 and CD8 T cell immune stimulation in all
patients. Clinical responses in monotherapy, in combina-
tion with chemotherapy and immune therapy are very
encouraging and initiation of Phase II studies are planned
for later this year.
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